Abstract
Introduction Since January 19, 2021, two vaccines against SARS-COV-2 are available in Brazil for emergency use for selected groups, not including children.
Aim To describe indirect impact on the number of hospitalized children with COVID-19 in the first three months after beginning of emergency use of two vaccines.
Methods A retrospective study was conducted in children (0-18 years), admitted in two pediatric hospitals of Rio de Janeiro city, between January and April 2021 with confirmed COVID-19 by reverse transcription polymerase chain reaction or serological tests. Number of cases, clinical signs, symptoms and outcomes were compared with the first wave of disease (April-June 2020). A p value of less than .05 were considered was significant.
Results The number of total admitted patients (with all diseases) were 1097 in 2020 period, being 46 (4.2%) of them with confirmed COVID-19, and 2187 in the 2021 period, with 47 (2.1%) cases (p=0.006). Predominant respiratory symptoms were present in 29/46 (63%) as the main presentation in 2020 patients and 37/47 (78.7%) in 2021 children (p=0.09). The main symptoms were fever, cough and dyspnoea in both periods. The median of lenght of stay after diagnosis were 4 days in 2020 and 2021 (p=0.9). Just one patient died in 2021.
Conclusion There was reduction of relative percentage of admitted confirmed pediatric cases in the the first three months of emergency use of two vaccines against SARS-COV-2, but it’s uncertain to atribute this finding to vaccination due to high circulation of the virus in the city.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding were supported to this research
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was submitted and approved by Ethics Committee of Faculty of Medicine (Universidade Federal Fluminense) and Prontobaby Group, under number 4.100.232 dated from June 20, 2020.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available for further analysis
